Yarrow Bioscience Files 8-K/A with Full Q2 2026 Financials and Pro Forma Merger Data
YARW has more than doubled off its 52-week low of $14.025.
Summary
Yarrow Bioscience filed an amended 8-K with full Q2 2026 financials for Pre-Merger Yarrow and pro forma combined statements, providing the detailed financial data behind today's earlier earnings release.
Key Events · Earnings and Guidance · YARW
-
Full Q2 2026 Financials Filed
Pre-Merger Yarrow reported a net loss of $6.5 million for Q2 2026 and $9.3 million for the first half of 2026, with R&D expenses of $4.9 million and G&A of $1.8 million for the quarter.
-
Pro Forma Combined Financials
Unaudited pro forma combined statements show a net loss of $15.7 million for the six months ended June 30, 2026, and a combined cash position of $112.8 million after giving effect to the merger and $100 million pre-closing financing.
-
Merger Accounting Details
The merger is accounted for as a reverse recapitalization with Yarrow as the accounting acquirer. VYNE's accumulated deficit of $776.6 million was derecognized, and transaction costs of $5.9 million were reflected.
-
Cash Runway Extended
Management estimates that the $100 million pre-closing financing proceeds, together with existing cash of $18.7 million as of June 30, 2026, will fund operations into 2028.
Analysis · YARW · Life Sciences
This amended 8-K provides the complete financial statements of Pre-Merger Yarrow for Q2 2026, recast to reflect the merger exchange ratio, along with unaudited pro forma combined financials. The press release earlier today summarized results, but this filing delivers the audited and unaudited financial statements, MD&A, and pro forma information that investors need to fully assess the combined company's financial position. The pro forma data shows a combined net loss of $15.7 million for the first half of 2026 and a cash position of $112.8 million after the merger and pre-closing financing, which is critical for evaluating the company's runway and valuation.
At the time of this filing, YARW was trading at $42.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.1M. The 52-week trading range was $14.03 to $46.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.